Chromatin immunoprecipitation (ChIP) studies were conducted in human hepatocytes treated with rifampicin in order to identify new pregnane-X receptor (PXR) target genes. Genes, both previously known to be involved and not known to be involved in drug disposition, with PXR response elements (PXREs) located upstream, within or downstream from their potentially associated genes, were identified. Validation experiments identified several new drug disposition genes with PXR binding sites. Of these, only CYP4F12 demonstrated increased binding in the presence of rifampicin. The role of PXR in the basal and inductive response of CYP4F12 was confirmed in hepatocytes in which PXR was silenced. We also assessed the association of PXR-coactivators and -corepressors with known and newly identified PXREs. Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment. We observed promoter-dependent patterns with respect to the binding of various coactivators and corepressors involved in the regulation of CYP4F12, CYP3A4, CYP2B6, UGT1A1 and P-glycoprotein. In conclusion, our findings indicate that PXR is involved in the regulation of CYP4F12 and that PXR along with SRC1 binds to a broad range of promoters but that many of these are not inducible by rifampicin.
INTRODUCTION
The human pregnane-X receptor (PXR, NR1I2) is an essential regulator of a large and growing array of drug disposition genes which correspond to all phases of drug metabolism. These include phase I enzymes such as cytochrome P450 (CYP), phase II enzymes such as uridine-5 0 -diphosphate glucuronosyltransferases (UGTs) and transporters such as the multidrug resistance protein MDR1 P-glycoprotein (Pgp) (1) . A large body of literature has revealed that PXR activation by xenobiotics, in the liver and intestine, results in a significant increase in the expression of drug metabolizing enzymes and transporters (1) (2) (3) (4) (5) . In addition to increased gene expression, PXR can repress gene expression (6) , indicating that gene regulation via PXR is complex. Although PXR functions as a defense mechanism against toxic insults, it also represents the molecular basis for pharmacokinetic drug-drug interactions. For example, if one drug activates PXR, administration of this drug can promote its own elimination (autoinduction) or the elimination of other coadministered drugs that are metabolized and eliminated by PXR-target gene products, thereby reducing the efficacy of drug therapies in patients on combination therapy (7) (8) (9) .
As a prototypical nuclear receptor, PXR has a DNAbinding domain (DBD) at the N-terminus and a ligandbinding domain (LBD) at the C-terminus. The DBD is responsible for binding to regulatory DNA sequences such as the AGGTCA-like direct repeats spaced by 3, 4 or 5 bases (DR3, DR4 and DR5), and the everted repeats separated by 6 or 8 bases (ER6 and ER8) located in the PXR target genes (10) . The LBD is multifunctional in that it is capable of ligand binding, dimerization, transcriptional activation, and interactions with transcriptional co-factors. The C-terminal helix termed AF-2 is responsible for transcriptional activation by recruiting coactivators through conformational rearrangement, or gene repression by interactions with transcriptional corepressors (7, 11) .
Understanding of coactivators and corepressors of PXR in the expression of target genes is relatively limited.
coactivators and corepressors involved in the PXR regulation of drug metabolizing enzymes and transporters. Small heterodimer partner (SHP/NC0B2) and nuclear receptor corepressor 2 (NCoR2/SMRT) were identified as corepressors, while steroid receptor coactivators 1 (SRC1/NCOA1) and 2 (SRC2/GRIP1), nuclear receptor interacting protein 1 (NRIP1/RIP140), peroxisome proliferator-activated receptor-gamma coactivator (PGC-1), and Forkhead transcription factor FKHR (FOXO1) were reported as coactivators.
While NCoR, SHP and SMRT are known to be corepressors of genes, studies undertaken by several groups using transfection assays in CV1, HepG2, HEK293 and yeast cells indicate that only SHP and SMRT are involved in transcriptional repression of PXR (13) (14) (15) (16) . Ourlin et al. (13) demonstrated in HepG2 cells that SHP blocks PXR binding to DNA in a ligand-dependent manner. In addition, their studies using transient transfection assays proved that increased expression of SHP resulted in a decrease in PXR activation in the presence of rifampicin.
Tirona et al. (17) highlighted the critical involvement of hepatocyte nuclear factor 4a (HNF4a), together with PXR in the regulation of CYP3A4. Using mammalian two-hybrid assays Li and Chiang (18) showed that HNF4a and SHP compete to interact with PXR. These studies also revealed that SHP only partially blocked the PXR/SRC1 interaction and was unable to block the PXR/ PGC-1a interaction. Using chromatin immunoprecipitation (ChIP) analysis, they observed that rifampicin increased the recruitment of HNF4a and SRC1 to the CYP3A4 chromatin but reduced PGC1a recruitment.
In most studies referenced above, cell lines in which proteins were overexpressed were not of hepatic origin and promoter elements were outside of their natural chromatin environment. In addition, to assess DNA-protein and protein-protein interactions researchers used electro mobility shift assays that make use of 'naked' DNA as a probe, whereas in living cells much of the DNA is covered by nucleosomes. Thus, many binding sites for a protein in living cells could be masked by the presence of nucleosomes, but they would be scored as positive by the biochemical assays (19) .
The goals of the experiments presented in this manuscript were 3-fold: First, using ChIP, we searched for new PXR target genes in cryopreserved primary human hepatocytes treated with rifampicin. Second, using ChIP-based assays, we studied binding of PXR, as well as PXRcorepressors and -coactivators to newly identified and established PXR response elements (PXREs) before and after treatment with rifampicin. Third, we investigated whether newly identified genes in the ChIP experiments were bona fide PXR target genes by measuring mRNA levels after small interfering RNA (siRNA)-mediated knockdown of PXR. 
MATERIALS AND METHODS

Materials
Cell culture and drug treatment
Cryopreserved primary human hepatocytes from three different donors (LHO: 68-year-old female Caucasian; 455: 37-year-old female Caucasian; and DMQ: 59-year-old African-American female) were used in our studies. Hepatocytes were plated in 6-well collagen-coated plates at a seeding density of 1.5 Â 10 6 cells per well in In VitroGRO-CP Media and 2.2% antibiotic/antimycotic Torpedo Mix and placed in an incubator (378C, 5% CO 2 ). After 24 h the plating medium was discarded and hepatocytes were treated for 3 h with either DMSO (0.1%) or rifampicin 10 mM, prepared in In VitroGRO-HI incubation Media and 2.2% antibiotic/antimycotic Torpedo Mix. Following the 3 h incubation period, hepatocytes were fixed with 1/10 formaldehyde solution (11% formaldehyde, 0.1 M NaCl, 1 M EDTA, 50 mM HEPES pH 7.9). Fixation was stopped by adding 1/20 volume of glycine solution (2.5 M glycine, water) to the existing media. Cells were washed, centrifuged (800g for 10 min.) and resuspended in phosphate buffered saline (PBS)-Igepal solution (0.5% Igepal in PBS). Thereafter, cells were centrifuged (800g for 10 min.) and again resuspended in PBS-Igepal to which 100 ml PMSF (100 mM in ethanol) was added. Cells were then centrifuged (800g for 10 min.), pelleted and snap-frozen on dry ice and stored at À808C for further analysis.
ChIP-based assays
In order to identify PXREs present on genes in the entire human genome, cross-linked chromatin from hepatocytes treated with DMSO (0.1%) or 10 mM rifampicin were immunoprecipitated against a validated-PXR antibody. Cloning, sequencing, analysis of tags and confirmation of the PXR-binding sites using polymerase chain reaction (PCR) primers (Supplementary Table S1 , Supplementary Data) targeting a region within 200 bp of each selected alignment were conducted as previously described (20) . Assays to confirm that increased PXR-binding resulted in increased transcription were undertaken by immunoprecipitating cross-linked chromatin against RNA polymerase II (Pol II) antibody and the enrichment of Pol II was determined by quantitative (q)-PCR (20) . To assess the involvement of coactivators and corepressors in the PXR-regulation of CYP3A4, CYP2B6, CYP4F12, UGT1A1 and MDR1 cross-linked chromatin was immunoprecipitated against the aforementioned coactivators and corepressors and the enrichment of SRC-1, SRC-3, GRIP1, NCOR, PGC1a, HNF4a, FKHR, RIP140, SMRT and SHP were determined by q-PCR.
RNA interference
Cryopreserved human hepatocytes (120 000 cells/well) were cultured in antibiotic-free In VitroGRO-HI plating medium in collagen-I coated 48-well plates. After 24 h ON-TARGETplus SMARTpool human NR1I2 siRNA (L-003415) was used to knockdown PXR. ON-TARGETplus GAPDH Control Pool siRNA (D-001830) and ON-TARGETplus Non-Targeting Pool siRNA (D-001810) were used as internal controls. Briefly, siRNA duplexes (100 nmol/well) and DharmaFect-1 (3 ml/well) were diluted in 50 ml antibioticand serum-free In VitroGRO-HI incubation medium separately and mixed gently and incubated for 5 min at room temperature. Afterward, PXR-siRNA and DharmaFect-1 were mixed (total volume 100 ml) and incubated at room temperature for 20 min. Then, 100 ml siRNA-DharmaFect-1 complex was diluted with 100 ml antibiotic-free medium and added to the well. Under these conditions, the transfected cells looked morphologically normal after 72 h, and they did not differ from untransfected cells in cell viability and levels of the 18S mRNA housekeeping gene (data not shown). Thereafter, hepatocytes were treated with 10 mM rifampicin or 0.1% DMSO (vehicle control) for 48 h. To ensure that functional and specific silencing was obtained, the mRNA levels of PXR and known PXR target genes (CYP3A4, CYP2B6, Pgp and UGT1A1) were compared between PXR-siRNA and SCR (scrambled) siRNA groups before and after treatments in all experiments. 
Reverse-transcription Q-PCR
Statistical analysis
The differences in PXR-, Pol II-, SRC-1-, SRC-3-, GRIP1-, NCOR-, PGC1a-, HNF4a-, FKHR-, RIP140-, SMRT-and SHP binding, between hepatocytes treated with 10 mM rifampicin or 0.1% DMSO (vehicle control) were analyzed using the Student's t-test. Statistical analysis of the differences in mRNA gene expression was based upon differences in the ÁC t values. Differences with P-values <0.05 were considered significant.
RESULTS
Identification of new PXR target genes
In order to identify new genes containing PXR binding sites, we performed ChIP analyses with cryopreserved human hepatocytes treated with the prototypical inducer rifampicin (10 mM, 3 h). The batches of hepatocytes used in these studies were selected for high inducibility of CYP3A4 mRNA (45-to 75-fold relative to vehicle control) after treatment with rifampicin (10 mM) for 48 h (data not shown). To validate the polyclonal anti-PXR antibody used for ChIP, the ability to detect known PXR target genes was determined (21): Enrichment of CYP3A4, CYP2B6, UGT1A1 and MDR1 PXRE were 3.9-, 4.2-, 2.2-and 1.5-fold higher in rifampicin as opposed to vehicle (control; 0.1% DMSO)-treated cells ( Figure 1A) . Remarkably, binding of PXR to all PXREs was also detected in the absence of rifampicin ( Figure 1A ), although binding was significantly lower than that after treatment with rifampicin. Measuring of PXR interaction to two untranscribed regions (Untr) served as negative controls. While ChIPs with a control IgG are often conducted as a negative control, our findings (data not shown) suggested that the values obtained using this approach provided a less reliable baseline than assaying negative control regions (Untr) with the experimental antibody. Also, we have observed that different antibodies have different levels of background (20) . Our unpublished data also suggest that antibody titration experiments do not necessarily show the expected concentrationdependent increase and then plateau, but one continues to see some increase (but not linear or proportional with the antibody amount) upon increasing the antibody amount. In our studies, we could not utilize much higher antibody amounts which we believe were already in excess.
A discovery approach for the identification of PXR binding sites in the human genome was initiated (see Materials and methods section). After chromatin precipitation with the anti-PXR antibody, $7300 tags representing anti-PXR immunoprecipitated DNA, which were derived from rifampicin-treated cells, was sequenced ( Figure 2 ). Approximately 5000 of these sequences produced acceptable genomic alignments from which 32.7% (or about 1/3) did not map within 10 kb of any gene. The number of genes that had at least one tag alignment within 10 kb was 3745 (using the NCBI gene database). Of these 3745 genes, 500 had two or more tag alignments (Supplementary Table S2 , Supplementary Data). For these 500 genes, there were a total of 1244 aligns (within AE10 kb), of which 877 (70.5%) mapped inside genes, 190 (15.3%) upstream and 177 (14.2%) downstream. Our analysis included all of these tags since PXRE sites may be important wherever they lie within the gene and do not necessarily need to be located in the 5 0 UTR. Because ChIP fragments were <600 bp, 1200 was set as the maximal distance between two tags representing the same binding site, such that $500 tags generated 182 clusters consisting of two or more distinct alignments within 1200 bp). Genes identified as known to contain PXR binding sites in their promoter regions were CYP3A4 and MDR1. As expected, the lack of identification of additional known PXR target genes indicated that the screen had not reached saturation.
The binding of PXR to identified genomic locations in cryopreserved hepatocytes treated with either vehicle or rifampicin was confirmed by q-PCR using PXR primers encompassing $200 nt of the putative PXR binding sites (Supplementary Table S1 , Supplementary Data). Of the 182 clusters, 12 clusters with strong PXR binding (>5-fold binding relative to the negative control region) were selected for further testing ( Table 1) . Several of these were not in the proximity of genes known to be involved in drug metabolism or transport but were involved in apoptosis, electron transport, hormone catabolic processes, response to chemical stimuli and steroid, estradiol, linoleic acid, retinol, tryptophan, arachidonic acid, fatty acid and lipid metabolism. In addition, 29 tags were selected which were in the proximity of genes known to be involved in different metabolic processes including drug metabolism, or recently identified as PXR target genes by gene profiling in studies with the colon carcinoma cell line LS180 (Table 1) (2) . Of the 41 tags/clusters selected, 23 showed elevated PXR binding (>5-fold increased binding compared to the negative control regions) ( Table 2) . Interestingly, of the 23 identified PXR-binding sites only 11 showed a trend towards increased PXR-binding in the presence of rifampicin compared to the vehicle (Table 2 and Figure 3A ). However, statistically significant differences were only observed for CYP4F12 and ABCC4.
In addition to assessing increased PXR-binding, we also determined whether increased PXR binding at the newly identified sites, as well as the previously identified literature controls, did result in increased binding of DNA-dependent RNA Pol II to these genes ( Figure 4 ). Determinations were performed in a ChIP-type assay Outline of the strategy for ChIP-cloning and filtering of sequences. 'Filter': short sequences (<40 bp), highly repetitive sequences and those with <90% identity to the genome were eliminated. 'Selection': 12 clusters with strong PXR binding (>5-fold binding relative to the negative control region) were selected for further testing. In addition, 29 tags were selected which were in the proximity of genes known to be involved in different metabolic processes including drug metabolism, or recently identified as PXR target genes by gene profiling in studies with the colon carcinoma cell line LS180 (Table 1 ) (2). GP0059_01_B10-frag003 Aldo-keto reductase family 1 member C1 acts in xenobiotic and progesterone metabolism, increased expression is observed in lung cancer, glaucoma and polycystic ovary syndrome.
(continued) Cluster 11-267 B-cell CLL/lymphoma 9-like, a BCL9-related protein that acts as a transcriptional regulator, induces b-catenin (CTNNB1) nuclear translocation epithelial to mesenchymal transition, enhances cell migration, expression is upregulated in colorectal tumors.
ARNT2
Cluster 15-179 Aryl-hydrocarbon receptor nuclear translocator 2, a protein that heterodimerizes with HIF-1alpha (HIF1A) and is involved in hypoxia-induced erythropoietin (EPO) expression. ASS1
Cluster 9-86 The protein encoded by this gene catalyzes the penultimate step of the arginine biosynthetic pathway. There are approximately 10-14 copies of this gene including the pseudogenes scattered across the human genome, among which the one located on chromosome 9 appears to be the only functional gene for argininosuccinate synthetase. Mutations in the chromosome 9 copy of ASS cause citrullinemia. Two transcript variants encoding the same protein have been found for this gene.
This gene is a member of the Ets family of transcription factors and of the ternary complex factor (TCF) subfamily. Proteins of the TCF subfamily form a ternary complex by binding to the the serum response factor and the serum reponse element in the promoter of the c-fos proto-oncogene. The protein encoded by this gene is a nuclear target for the ras-raf-MAPK signaling cascade.
(continued) using an antibody against RNA Pol II (20). CYP4F12 showed a trend towards increased Pol II binding in the presence of rifampicin. However, ABCC4, UGT1A5, CARS, BMP1, TGIF2, BCL9L, CLG, GLDC and ABCB4 showed no change. As expected, both CYP3A4 and CYP2B6 showed a $2-fold increase in binding of Pol II (Figure 4 ). The increase observed for UGT1A1 and MDR1 was not significant. In order to study the correlation between Pol II binding by ChIP and mRNA levels, we also conducted quantitative mRNA analysis using TaqMan following treatment of hepatocytes with rifampicin for 3 or 48 h ( Figure 5 ). While increases in mRNA expression were observed as early as 3 h, the expression was significantly higher after 48 h of drug treatment. CYP3A4, CYP2B6, CYP4F12, MDR1 and UGT1A1 demonstrated 4.8-, 5.6-, 1.9-, 2.7-and 2.1-fold higher levels of mRNA expression after 48 h compared to 3 h drug treatment. Differences in mRNA levels between genes did not correlate with the Pol II ChIP experiments. The antibody used in these analyses is against phospho-Ser 2 in the C-terminal domain of Pol II, which is the elongating form of the polymerase. The analysis was not done at the transcription start site of the genes of interest as it is known that Pol II may be bound at that area but not transcribing (22) . Interestingly, the relative difference in mRNA accumulation after 3 and 48 h of treatment were most pronounced for CYP3A4 and CYP2B6.
PXR knockdown in human hepatocytes
We conducted siRNA studies to further discern the involvement of PXR in the regulation of CYP4F12, UGT1A5, ABCB4 and ABCC4 which were identified as having strong PXR binding sites using ChIP analysis. We observed 79% knockdown in PXR mRNA levels in hepatocytes transfected for 72 h with PXR-siRNA relative to hepatocytes that were transfected with SCR-siRNA (data not shown). The basal expression levels of known PXR target genes, such as CYP3A4, CYP2B6, MDR1 and UGT1A1 were significantly lower (54-97%) in hepatocytes in which PXR was knocked down using PXR-siRNA compared to non-specific SCR-siRNA ( Figure 6A) . A statistically significant ($80%, P < 0.05) decrease was also observed in the basal expression of CYP4F12. While $30% decrease was observed in the basal expression of UGT1A5, this was not statistically significant when compared to hepatocytes transfected with the non-specific SCR-siRNA. To confirm the specificity of the PXRsiRNA we also determined whether basal expression levels of the housekeeping genes 18S and GAPDH were affected. We did not observe a statistically significant decrease in the expression of these genes (data not shown) following PXR-siRNA transfection.
A comparison of fold changes in gene expression in hepatocytes transfected with either SCR-siRNA or PXR-siRNA demonstrated a statistically significant decrease in the inductive response of CYP3A4 and CYP2B6 when treated with the prototypical PXR activator rifampicin ( Figure 6B ). We also observed a statistically significant decrease in the inductive response of CYP4F12 in hepatocytes transfected with SCR-siRNA or PXRsiRNA following treatment with rifampicin. No significant difference was observed in the expression of UGT1A1, MDR1, UGT1A5, ABCB4 and ABCC4 in SCR-versus PXR-transfected siRNA. The inductive response that we observed for UGT1A5, ABCB4 and ABCC4 in rifampicin-treated hepatocytes transfected with SCR-siRNA relative to DMSO control without subsequent knockdown in PXR-siRNA-transfected hepatocytes may be related to the regulation of these genes by other transcription factors, such as the vitamin-D receptor (VDR), farsenoid-X receptor (FXR) and aryl hydrocarbon receptor (AHR) (23) (24) (25) .
Association of corepressors and coactivators with PXR binding sites
It was previously demonstrated that the steroid receptor complex protein SRC1 associates with PXR after ligand binding (26) . Using a similar approach as used to determine PXR-binding to PXR gene promoters, we assessed whether the level of binding of SRC1 was increased after the treatment of cells with rifampicin. A very similar binding pattern to that observed with the anti-PXR antibody was observed in which increased binding was found for all four genes analyzed ( Figure 1B ). In addition, we assessed the association of SRC1 with the 11 genes showing increased binding to PXR after exposing the cells to rifampicin (Table 2) . Again, binding patterns were very similar to those found for PXR ( Figure 3B ). In most cases, lower binding was detectable in cells not treated with rifampicin. Of the 11 genes tested, only CYP4F12 demonstrated significantly increased binding for both PXR and SRC1 after rifampicin treatment in three batches of hepatocytes. We extended our studies to assess the involvement of other previously published coactivators and corepressors of PXR on the regulation of CYP3A4, CYP2B6, CYP4F12, UGT1A1 and MDR1. ChIP analysis was performed with antibodies specific for the coactivators GRIP1, SRC3, PGC1a, FKHR and RIP140, and the corepressors NCoR, SMRT and SHP. All antibodies used have been evaluated by others before (see Material and methods section) and specificity was confirmed using known target genes (data not shown).
Compared to the coactivators and corepressors that we assessed, HNF4a showed a significantly higher binding to the promoter elements of CYP3A4, CYP2B6, CYP4F12, UGT1A1 and MDR1 (Figures 7 and 8 ), but no increased binding of HNF4a was detectable after treatment of cells with rifampicin. In fact, the converse was true in that of the five genes evaluated, two (CYP3A4 and CYP4F12) showed a significantly decreased binding in the presence of rifampicin (Figure 7) .
None of the other coactivators that we assessed showed a statistically significant increase in binding in cells treated with rifampicin versus vehicle control. Interestingly, GRIP1 showed a decrease in binding to CYP4F12 in the presence of rifampicin. Of the corepressors tested, while a trend towards decreased binding of SHP was observed for CYP3A4 ( Figure 8A ), CYP2B6 ( Figure 8B ) and UGT1A1 ( Figure 8D ), we observed a statistically significant decrease only for MDR1 ( Figure 8C ).
DISCUSSION
Here we report the identification of new genes containing PXR binding sites using ChIP-based assays in cryopreserved primary human hepatocytes. The use of ChIP can detect the direct association of PXR and coactivators/corepressors with promoter elements. This is different from gene profiling experiments with cells treated with PXRactivators where it cannot be excluded that the induction of genes is a secondary effect of PXR activation. Our studies indicate that PXR binds to PXREs in the presence and absence of rifampicin, and that binding of PXR to many of the newly identified genes does not increase after treatment with rifampicin. The ability of PXR to regulate the basal expression and inducibility of one of these new genes, CYP4F12, was confirmed by hepatocytes depleted of PXR by siRNA. Finally, we extended our studies and also found that binding of SRC1 correlates with transcriptional activation of PXR target genes, whereas this was not found for other coactivators or corepressors studied.
Using a ChIP-based discovery approach, we were able to identify genes containing PXR binding sites which were mapped against the entire human genome (Supplementary  Table S2 , Supplementary data). Tags were identified U n t r 5 U n t r 2 0 metabolism (27) . For instance, PXR binds to FOXA2 (Supplementary Table S2 , Supplementary Data) and represses its' activity and the genes encoding the key enzymes in energy metabolism. Furthermore, Dai et al. (28) observed that ACC1 (Acetyl CoA carboxylase 1), which is a lipogenic enzyme, was consistently lower in PXR-null mice than wild-type mice. Their data indicated that PXR is involved in the regulation of ACC-1 gene expression during liver regeneration.
Using the data obtained in the ChIP-based discovery approach we were able to confirm that several previously unidentified drug disposition genes contain PXREs (Table 2 ). These included phase I (CYP4F12) and phase II (SULT1B1 and UGT1A5) drug metabolizing enzymes, as well as transporters (SLC40A1 and ABCB4). In addition, our data also confirmed previous studies which indicated that CYP3A5, CYP2C8 and GSTT1 were PXR-target genes (Table 2) (1, 2, 29) . Similar to what we observed for the genes with known PXR-binding sites ( Figure 1A) , PXR binding to the PXREs on 11 genes analyzed in Figure 3A also occurred in the absence of rifampicin. To ensure that our findings were not due to the high inducibility of PXR in the cells we used in our experiments, we have looked at binding to several targets in two to three batches of hepatocytes. The data indicated that results were consistently in agreement. While our discovery approach identified many new genes binding to PXR, the number of tags sequenced likely did not reach saturation, and therefore more PXR target genes may be identified in the future.
As expected, in our PXR antibody validation studies with known PXR-binding sites, all four genes showed significantly higher PXR binding than was observed for the control regions ( Figure 1A) . Similar to what we observed during the discovery approach, binding of PXR to these PXREs was also detected in the absence of rifampicin in which the binding to MDR1 was much higher than that to UGT1A1, CYP2B6 and CYP3A4. Our PXR knockdown studies add additional evidence of PXR binding to PXREs in the absence of ligand and the subsequent reduction in the basal expression of CYP3A4, CYP2B6, UGT1A1, Pgp and CYP4F12 ( Figure 6 ). This is in line with findings by Squires et al. (30) that PXR was present in the nucleus of mouse liver cells prior to the addition of a ligand. Similarly, in primary human hepatocytes in which PXR was knocked down using the hPXR-siRNA-adenovirus expression system, Kojima et al. (31) observed a reduction in the basal expression of CYP3A4 and CYP2B6 mRNA levels.
Our studies did confirm that addition of rifampicin significantly increased the binding of PXR to the PXREs of CYP3A4, MDR1, UGT1A1 and CYP2B6. Interestingly, the fold increase of PXR binding to PXRE was severalfold higher for CYP3A4 than was observed for MDR1 ( Figure 1A ). This may explain why minimal induction of MDR1 was observed after treatment with rifampicin compared to CYP3A4 ( Figure 5 ). Also of interest was the finding that PXR binding to PXREs did not always significantly increase in the presence of rifampicin (Figure 3 ) which subsequently did not result in an increase in gene transcription (Figure 4) . This phenomenon is difficult to explain and could be related to the fact that PXR binding to PXREs occurs in the absence of the ligand which could lead to saturation of PXREs on specific genes (30) . It should also be noted that PXR binding to PXREs is not the only determinant of an increase in gene transcription but involves numerous corepressors and coactivators (12) .
Using ChIP we identified CYP4F12 as having PXRbinding sites. We confirmed the involvement of PXR in the regulation of CYP4F12 by assessing its' basal expression and inducibility in human hepatocytes in which PXR was knocked down. CYP4F12 mRNA has been detected in several major tissues involved in drug disposition including the liver, kidney and small intestine (32, 33) . It is the only member of the CYP4F family involved in xenobiotic metabolism. In particular, CYP4F12 has been shown to be highly efficient toward metabolism of antihistaminic compounds, such as ebastine and terfenadine (32, 34, 35) . In addition to xenobiotics, CYP4F12 is also involved in the oxidation of arachadonic acid and stable prostaglandin H2 (PGH 2 ) analogs (32, 34) . Previous studies have highlighted the importance of the coactivator SRC-1 in PXR activation and the subsequent increase in gene transcription (36) . Our studies confirmed that the SRC-1 binding pattern mirrors that observed with PXR ( Figures 1B and 3B ). Similar to PXR, SRC-1 binding was increased after treatment of hepatocytes with rifampicin. This is in line with crystallographic studies which demonstrated that SRC-1 binds to PXR and stabilizes the PXR-LBD and together with the ligand exerts an additive effect on the stability of the receptor (36) . Binding of SRC-1 to the surface of PXR limits the ability of the receptor to continuously change its conformation and helps trap a single, active conformation of the ligand.
In addition to SRC-1, several other PXR-coactivators and -corepressors have been implicated in PXR-mediated gene regulation. These include the coactivators GRIP1, PGC1a, FKHR and RIP140, and the corepressors SMRT and SHP (12) . Analysis of these coactivators and corepressors did, in most cases, show significant binding to the promoter elements of the target genes in the absence of rifampicin compared to the control Untr (Figure 8) . Treatment of the hepatocytes with rifampicin did not result in a consistent increase in binding in the case of coactivators or decreased binding in the presence of corepressors. This may be related to our studies being conducted in human hepatocytes and not in a recombinant in vitro system. In comparison, studies by others were conducted in cell lines in which proteins were overexpressed and were outside their natural chromatin environment (13-16) . Overall, however, our data suggests that binding of the coactivators and corepressors studied were involved in the regulation of gene expression as binding was higher than to the negative control and, with few exceptions, the overall pattern of binding to the various promoter elements studied were similar. An important point to consider is that all our analyses were done after treatment of hepatocytes with rifampicin and we cannot exclude that different binding behavior could be found in the presence of other PXR activators. HNF4a has been shown to cooperate at the À7.8 kb XREM in the PXR-dependent induction of CYP3A4 expression (17) . Even though HNF4a binding was detectable in the presence and absence of rifampicin, it was unexpected that we observed a decrease in binding of HNF4a in the presence of rifampicin (Figure 7) . The role of HNF4a in PXR-mediated gene activation is not clear as Li and Chiang (18) and Tegude et al. (37) have shown that binding of HNF4a to the XREM-DR1 element is not required for gene activation of the CYP3A4 promoter. This was confirmed in a study by Kamiyama et al. (38) in which HNF4a was knocked down using an adenovirus expressing system in human hepatocytes. They observed that hHNF4a-siRNA did not significantly affect the fold-induction of CYP2B6, CYP2C8, CYP2C9 or CYP3A4 mRNA levels following treatment with CYP inducers, such as phenobarbital, rifampicin and dexamethasone. There is strong evidence, however, that HNF4a is involved in regulating basal expression of CYP3A4 (37, 38) .
In conclusion, in cryopreserved primary human hepatocytes we identified several new genes containing PXR binding sites. We confirmed the involvement of PXR in the regulation of CYP4F12 using siRNA. We also found that the SRC-1 binding pattern is very similar to PXR and that both bind to promoter elements in the absence of ligand. Finally, we did not observe a pattern correlating with rifampicin treatment with respect to other PXR coactivators/corepressors involved in gene regulation in the presence of rifampicin.
FUNDING
Funding for open access charge: Merck & Co., Inc.
Conflict of interest statement. None declared.
